Skip to main content
SpringerLink
Log in

KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Purpose

Glioma is the most common malignant primary tumor in the central nervous system (CNS). KIF3C, a motor protein of the kinesin superfamily, is highly expressed in the CNS. Although KIF3C has been identified as a potential therapeutic target in malignant cancers, the expression and function of KIF3C in glioma remains unclear.

Methods

The clinical characteristics of 53 patients with graded glioma (WHO I–IV) were analyzed in this study. The expression of KIF3C in glioma was evaluated by immunohistochemistry (IHC). Survival analysis was compared between higher and lower KIF3C expression groups. Data regarding the expression of KIF3C and survival analysis were also confirmed using the database from The Cancer Genome Atlas (TCGA). The potential mechanism of the regulation of tumor growth by KIF3C was investigated by an analysis of the public database from Oncomine.

Results

Expression of the KIF3C protein was higher in the low-grade glioma (LGG) group (n = 20) than that in the high-grade glioma (HGG) group (n = 33) (P < 0.05). Glioma patients with higher expression of KIF3C had longer survival time (P < 0.05). The subgroup analysis showed that higher KIF3C expression predicted longer survival time in the LGG group (P < 0.05). These clinical results were consistent with those in the TCGA database. Bioinformatics analysis showed that the KIF3C mRNA expression was upregulated significantly in response to PI3K/AKT/mTOR pathway inhibition.

Conclusion

This study demonstrated that KIF3C might inhibit glioma growth to prolong survival time by regulating the PI3K/AKT/mTOR pathway, providing a potential therapeutic target in glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:41–49. https://doi.org/10.1093/neuonc/nos218

    Article  Google Scholar 

  2. Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232:165–177. https://doi.org/10.1002/path.4282

    Article  PubMed  PubMed Central  Google Scholar 

  3. Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF Jr (2019) Glioblastoma and increased survival with longer chemotherapy duration. Kans J Med 12(3):65–69

    PubMed  PubMed Central  Google Scholar 

  4. Saito T, Sugiyama K, Takeshima Y, Amatya VJ, Yamasaki F, Takayasu T, Nosaka R, Muragaki Y, Kawamata T, Kurisu K (2018) Prognostic implications of the subcellular localization of survivin in glioblastomas treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurosurg 128:679–684. https://doi.org/10.3171/2016.11.JNS162326

    Article  CAS  PubMed  Google Scholar 

  5. Goldstein LS, Yang Z (2000) Microtubule-based transport systems in neurons: the roles of kinesins and dyneins. Annu Rev Neurosci 23:39–71. https://doi.org/10.1146/annurev.neuro.23.1.39

    Article  CAS  PubMed  Google Scholar 

  6. Hirokawa N (1998) Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 279:519–526. https://doi.org/10.1126/science.279.5350.519

    Article  CAS  PubMed  Google Scholar 

  7. Hirokawa N, Noda Y (2008) Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics. Physiol Rev 88:1089–1118. https://doi.org/10.1152/physrev.00023.2007

    Article  CAS  PubMed  Google Scholar 

  8. Hirokawa N, Takemura R (2005) Molecular motors and mechanisms of directional transport in neurons. Nat Rev Neurosci 6:201–214. https://doi.org/10.1038/nrn1624

    Article  CAS  PubMed  Google Scholar 

  9. Malicki J, Besharse JC (2012) Kinesin-2 family motors in the unusual photoreceptor cilium. Vision Res 75:33–36. https://doi.org/10.1016/j.visres.2012.10.008

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yang Z, Roberts EA, Goldstein LS (2001) Functional analysis of mouse kinesin motor Kif3C. Mol Cell Biol 21:5306–5311. https://doi.org/10.1128/MCB.21.16.5306-5311.2001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Teng J, Rai T, Tanaka Y, Takei Y, Nakata T, Hirasawa M, Kulkarni AB, Hirokawa N (2005) The KIF3 motor transports N-cadherin and organizes the developing neuroepithelium. Nat Cell Biol 7:474–482. https://doi.org/10.1038/ncb1249

    Article  CAS  PubMed  Google Scholar 

  12. Keil R, Kiessling C, Hatzfeld M (2009) Targeting of p0071 to the midbody depends on KIF3. J Cell Sci 122:1174–1183. https://doi.org/10.1242/jcs.045377

    Article  CAS  PubMed  Google Scholar 

  13. Sardella M, Navone F, Rocchi M, Rubartelli A, Viggiano L, Vignali G, Consalez GG, Sitia R, Cabibbo A (1998) KIF3C, a novel member of the kinesin superfamily: sequence, expression, and mapping to human chromosome 2 at 2p23. Genomics 47:405–408. https://doi.org/10.1006/geno.1997.5123

    Article  CAS  PubMed  Google Scholar 

  14. Yang Z, Goldstein LS (1998) Characterization of the KIF3C neural Kinesin-like motor from mouse. Mol Biol Cell 9:249–261. https://doi.org/10.1091/mbc.9.2.249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gumy LF, Chew DJ, Tortosa E, Katrukha EA, Kapitein LC, Tolkovsky AM, Hoogenraad CC, Fawcett JW (2013) The kinesin-2 family member KIF3C regulates microtubule dynamics and is required for axon growth and regeneration. J Neurosci 33:11329–11345. https://doi.org/10.1523/JNEUROSCI.5221-12.2013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wang C, Wang C, Wei Z, Li Y, Wang W, Li X, Zhao J, Zhou X, Qu X, Xiang F (2015) Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF-β signaling. Cancer Lett 368:105–114. https://doi.org/10.1016/j.canlet.2015.07.037

    Article  CAS  PubMed  Google Scholar 

  17. Navone F, Consalez GG, Sardella M, Caspani E, Pozzoli O, Frassoni C, Morlacchi E, Sitia R, Sprocati T, Cabibbo A (2001) Expression of KIF3C kinesin during neural development and in vitro neuronal differentiation. J Neurochem 77:741–753. https://doi.org/10.1046/j.1471-4159.2001.00277.x

    Article  CAS  PubMed  Google Scholar 

  18. Liu Z, Rebowe RE, Wang Z, Li Y, Wang Z, DePaolo JS, Guo J, Qian C, Liu W (2014) KIF3a promotes proliferation and invasion via Wnt signaling in advanced prostate cancer. Mol Cancer Res 12:491–503. https://doi.org/10.1158/1541-7786.MCR-13-0418

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Huang X, Liu F, Zhu C, Cai J, Wang H, Wang X, He S, Liu C, Yao L, Ding Z, Zhang Y, Zhang T (2014) Suppression of KIF3B expression inhibits human hepatocellular carcinoma proliferation. Dig Dis Sci 59:795–806. https://doi.org/10.1007/s10620-013-2969-2

    Article  CAS  PubMed  Google Scholar 

  20. De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69:8035–8042. https://doi.org/10.1158/0008-5472.CAN-09-1224

    Article  CAS  PubMed  Google Scholar 

  21. Son HJ, Choi EJ, Yoo NJ, Lee SH (2019) Somatic frameshift mutations of cancer-related genes KIF3C and BARD1 in colorectal cancers. Pathol Res Pract 215:152579. https://doi.org/10.1016/j.prp.2019.152579

    Article  PubMed  Google Scholar 

  22. Harada M, Ishihara Y, Itoh K, Yamanaka R (2007) Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep 17:629–636. https://doi.org/10.3892/or.17.3.629

    Article  CAS  PubMed  Google Scholar 

  23. Schmid RS, Simon JM, Vitucci M, McNeill RS, Bash RE, Werneke AM, Huey L, White KK, Ewend MG, Wu J, Miller CR (2016) Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide. Neuro Oncol 18:962–973. https://doi.org/10.1093/neuonc/nov321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Muresan V, Abramson T, Lyass A, Winter D, Porro E, Hong F, Chamberlin NL, Schnapp BJ (1998) KIF3C and KIF3A form a novel neuronal heteromeric kinesin that associates with membrane vesicles. Mol Biol Cell 9:637–652. https://doi.org/10.1091/mbc.9.3.637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Gersey Z, Osiason AD, Bloom L, Shah S, Thompson JW, Bregy A, Agarwal N, Komotar RJ (2019) Therapeutic targeting of the notch pathway in glioblastoma multiforme. World Neurosurg. https://doi.org/10.1016/j.wneu.2019.07.180

    Article  PubMed  Google Scholar 

  26. Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7:33440–33450. https://doi.org/10.18632/oncotarget.7961

    Article  PubMed  PubMed Central  Google Scholar 

  27. Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16:100. https://doi.org/10.1186/s12943-017-0670-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wojtas B, Gielniewski B, Wojnicki K, Maleszewska M, Mondal SS, Nauman P, Grajkowska W, Glass R, Schüller U, Herold-Mende C, Kaminska B (2019) Gliosarcoma is driven by alterations in PI3K/Akt, RAS/MAPK pathways and characterized by collagen gene expression signature. Cancers 11(3):E284. https://doi.org/10.3390/cancers11030284

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study is supported by Grants from the Foundation of Shanghai anti cancer association (No. SACA-CY19C05), the National Natural Science Foundation of China (No. 81802494) the Shanghai Natural Science Foundation (No. 16ZR1406300) and Wu Jieping Medical Foundation (320.6750.17150).

Author information

Author notes

  1. Yang Gao, Liangdong Li and Hui Zheng have contributed equally to this work.

Authors and Affiliations

  1. Department of Neurosurgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China

    Yang Gao, Liangdong Li, Changshuai Zhou, Xin Chen, Bin Hao & Yiqun Cao

  2. Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, 200072, China

    Hui Zheng

Authors
  1. Yang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liangdong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hui Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changshuai Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xin Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bin Hao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yiqun Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yang Gao or Yiqun Cao.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The present study was approved by the Ethics Committee of Fudan University Shanghai Cancer Center. All procedures performed in the present study were in accordance with the 1964 Helsinki Declaration and its later amendments.

Informed consent

Informed consent was not sought, since a retrospective design was used.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file 1 (DOCX 18 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, Y., Li, L., Zheng, H. et al. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K/AKT/mTOR pathway. J Neurooncol 146, 513–521 (2020). https://doi.org/10.1007/s11060-020-03399-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-020-03399-7

Keywords

Search

Navigation